

Notes of: Meeting of the Northern and Eastern Devon Formulary Interface Group

Thursday 25th April 2013, 9:00am – 11:00am. Castle Place Surgery, Tiverton EX16 6 NP

Present	Chris Roome (CR)– Head of Clinical Effectiveness, Chair	NEW Devon CCG
	Gareth Franklin (GF) – Clinical Guidance Manager	NEW Devon CCG
	Sam Smith (SS) – Locality Medicines Optimisation Pharmacist	NEW Devon CCG
	Iain Carr (IC) – Medicines Optimisation Pharmacist	NEW Devon CCG
	Stephen Hunt (SH) – GP, Waterside Practice	NEW Devon CCG
	Hugh Savill(HS) – GP, Castle Place Surgery	NEW Devon CCG
	Bernie Wathen (BW) – Formulary Pharmacist	NDDH
	Simon Kay (SK) – GP, Haldon House Surgery	NEW Devon CCG
	Andrew Harrison (AH) – GP, The South Lawn Medical Practice	NEW Devon CCG
	Stephen Myers (SM) – GP, Boutport Street Surgery	NEW Devon CCG
	Tawfique Daneshmend (TD)– DTC Chair/Consultant Gastroenterologist	RD&E
	Beverly Baker (BB) – Non Medical Prescribing Lead	NEW Devon CCG
	Amanda Gulbranson (AG)– Clinical Effectiveness Lead	DPT
	Carol Webb (CW) – Joint Formularies Technician	NEW Devon CCG

Apologies	Carol Albury (CA) - Locality Medicines Optimisation Pharmacist	NEW Devon CCG
	Tracey Foss (TF) – Director of Pharmacy	RD&E
	Matt King (MK) – GP, Coleridge Medical Centre	NEW Devon CCG
	Stuart Kyle (Sky) – DTC Chair / Consultant Rheumatologist	NEW Devon CCG
	Ross Mitchell (RM)	Dorset Healthcare
	Petrina Trueman- Joint Formularies Pharmacist	NEW Devon CCG
	Darunee Whiting (DW) – GP, Northam Surgery	NEW Devon CCG

1. Welcome and Apologies – noted above

2. Notes of previous meetings

7th March 2013 (NE Joint Formulary) and 28th March 2013 (ExEJF). Both agreed.

Outstanding action from the NE Joint Formulary:

Dermatology section to be sent to the Dermatologists

GF

There was discussion about the dissemination of the information in the formulary. It was decided that frequent, short, news-flash style, information was better.

3. Future Chair and Committee membership

As this new formulary group has been formed the membership and chair needs to be agreed. The cost impact for each attendee needs to be assessed by the localities. It was agreed that six GPs would be involved; two from Northern Locality and four from Eastern Locality, if that is affordable. Secondary care input should be the chair from NDDH and RD&E Drugs & Therapeutics Committee, providing clinician representation, with a potential for a second secondary care consultant from each trust.

To approach Susie Harris about membership on this group

TD

Devon Partnership Trust, AG is happy to act as the link for this Trust.

	<p>The non-clinical membership of FIG was discussed.</p> <p>Terms of Reference need to be drafted with a draft membership to be included and to be presented to the locality leads</p>	<p>GF</p>
<p>4.</p>	<p>Recent drug approvals</p> <p>a) NDDH DTC Argatroban was approved as per RD&E. Funded by secondary care</p> <p>b) RD&E DTC Anidulafungin was approved, PbR excluded. It was noted that future applications for items funded by the commissioners will be decided at the Clinical Policy Committee Infloran was approved, funded by secondary care Cyanokit was approved, funded by secondary care</p> <p>c) Clinical Policy Committee – first meeting scheduled for the 7th May</p> <p>d) PHTCG Capsaicin 8% patches (Qutenza), this was commissioned</p> <p>e) Exeter & Eastern Devon Joint Formulary (final meeting) Fluticasone Furoate (Avamys) nasal spray, to be added second line to beclometasone This will be a standing item on future agenda</p>	
<p>5.</p>	<p>Infant feeds guidance</p> <p>This was agreed to go into the Formulary. This is part of a much large guidance document which could be linked to from the Formulary. There was discussion about ensuring that Health visitors are aware of this guidance and comply with it. North Devon contact details to be added.</p> <p>To be added to the current Exeter & Eastern formulary which the North Devon Formulary can link to</p> <p>To find out if Health Visitors are contracted to follow the local formularies</p>	<p>CW/BW</p> <p>GF</p>
<p>6.</p>	<p>Glucose test strips</p> <p>This pilot about the choice of blood glucose testing machines is being conducted in GP practices. The objective is to see how current patients can be switched to these machines. It was agreed that new patients could start using these machines straight away, but that switching current patients should wait until the pilot has been concluded.</p> <p>Guidance to be added to the Formulary – for new patients</p>	<p>CW</p>
<p>7.</p>	<p>New anticoagulation guidance (Peninsula)</p> <p>This guidance has been amended with the addition of Apixaban.</p> <p>To be sent to BW to added to the current North Devon Formulary</p> <p>There was discussion about the up dated licensing of Rivaroxaban for treatment of DVT. It was noted that a piece of work had been done in Plymouth.</p> <p>To bring together a working group to assess the implications for the use of Rivaroxaban for treatment of DVT</p>	<p>CW/BW</p> <p>GF/IC/CA</p>
<p>8.</p>	<p>Proposed process for formulary merger across Northern and Eastern</p> <p>The attached document was briefly outlined. Chapters 8 Malignant Disease and Chapter 15 Anaesthetics, it was agreed that these were mostly secondary care drugs and that may be just a list of drugs and</p>	

	links through to relevant documents and NICE guidelines. Formulary websites were discussed and it was agreed that the move to the new website should be as soon as possible. The new site would be hidden and the two old sites kept live until at least 50% of the new formulary is complete.	
	Link to the NHS England website to be added to the new formulary website	CW
9.	Mental health guidance in the NE Joint Formulary Differed to next meeting	
10.	Palliative care guidance in the NE Joint Formulary Differed to next meeting	
11.	Entry of NICE Technology Appraisals into the NE Formulary- A summary of the Devon-wide NICE commissioning and assurance process This was noted, the process involves all providers	
12.	NICE Technology Appraisals – March Noted	
13.	MHRA Drug Safety Update – March To add to the formulary the note about Dabigatran	CR
14.	Any other business Prescribers are being asked to prescribe Mirabegron To send a reminder email to the urologists that mirabegron is not currently on the formulary There is concern within secondary care on how to apply to the Clinical Policy Committee. To send information on the application process to the Clinical Policy Group to clinicians	CR CR
Next meeting: 23 May 2013, Castle Place Surgery, Tiverton EX16 6NP		

Northern & Eastern Formulary – Action Log			
Date	Action	Responsible	
March 2013	Dermatology section to be sent to the Dermatologists	GF	
April 2013	Future Chair and Committee membership An elderly care consultant or acute physician would also be appropriate on the membership To approach Susie Harris about membership on this group Terms of Reference need to be drafted with a draft membership to be included and to be presented to the locality leads	TD GF	Completed Completed
April 2013	Infant Feeds Guidance: To send to BW, to be added to the current Exeter & Eastern formulary which the North Devon Formulary can link to To find out if Health Visitors are contracted to follow the local formularies	CW/BW GF	 Completed
April 2013	Blood glucose strips Guidance to be added to the Formulary – for new patients	CW	Completed
April 2013	New anticoagulation guidance (Peninsula) To be sent to BW to added to the current North Devon Formulary To bring together a working group to assess the implications for the use of Rivaroxaban for treatment of DVT	CW?/BW GF/IC/CA	Completed
April 2013	Link to the NHS England decisions to be added to the new formulary website	CW	
April 2013	MHRA Drug Safety Update – March To add to the formulary the note about Dabigatran	CW	
April 2013	To send a reminder email to the urologists that mirabegron is not in the formulary and not to ask GPs to prescribe and that NICE is due to be published in July	CR	Completed
April 2013	To send information on the application process to the Clinical Policy Group to clinicians	CR	Completed